presseportal.de : First Head to Head Study Comparing Crestor(TM) an...
Geschrieben von rootam 16.01.2008 05:58:45 (46 x gelesen)
AstraZeneca: London (ots/PRNewswire) - AstraZeneca (LSE: AZN) (NYSE: AZN) today announced the launch of a new clinical trial, SATURN, designed to measure the impact of CRESTOR(TM) (rosuvastatin) 40 mg and atorvastatin (Lipitor(R)) 80 mg on the progression ...